银丹心泰滴丸治疗冠心病心绞痛的成本-效益分析
x

请在关注微信后,向客服人员索取文件

篇名: 银丹心泰滴丸治疗冠心病心绞痛的成本-效益分析
TITLE:
摘要: 目的:从全社会角度评价银丹心泰滴丸用于治疗冠心病心绞痛的经济性。方法:在各大数据库公开发表的文献中选择与银丹心泰滴丸有关的治疗方案及其对照方案,并从文献中获取治疗方案的成本和临床效果数据。采用条件价值评估法获取居民对冠心病心绞痛治疗药物的支付意愿,通过构建计量经济学模型将临床效果信息转换为治疗效益,最后采用净效益值和增量净效益值两个指标来评价方案的经济性。结果与结论:当银丹心泰滴丸单独使用时,其净效益>0,具有经济性,且以56 d为疗程的治疗方案优于以28 d为疗程的治疗方案;当银丹心泰滴丸联合硝酸甘油片、单硝酸异山梨酯缓释片、辛伐他汀分散片等药品使用时,其增量净效益大于对照方案,具有较高的经济性。
ABSTRACT: OBJECTIVE: To evaluate the economics of Yindan xintai dropping pills in the treatment of angina pectoris caused by coronary heart disease from societal perspectives. METHODS: Therapy regimens related to Yindan xintai dropping pills and control regimens were selected from published literatures included in database, and the cost of therapy regimens and clinical effect data were extracted from literatures. Contingent evaluation method was used to measure people’s willingness-to-pay for angina pectoris treatments. An econometric model was conducted to transfer the effectiveness data to benefit data. The economics of treatment was evaluated depending upon net benefit or incremental net benefit indicator. RESULTS & CONCLUSIONS: When Yindan xintai dropping pills is used alone, its net benefit is >0, indicating economical advantage; 56 d therapy regimen is better than 28 d therapy. When Yindan xintai dropping pills were combined with glyceryl trinitrate tablet, Isosorbide mononitrate sustained-release tablet, Simvastatin dispersible tablet and other drugs, its incremental net benefit is better than control regimens and has good economics.
期刊: 2016年第27卷第5期
作者: 伍红艳,汤 磊
AUTHORS: WU Hongyan,TANG Lei
关键字: 银丹心泰滴丸;冠心病心绞痛;成本-效益分析;条件价值评估法;净效益值;增量净效益值
KEYWORDS: Yindan xintai dropping pills; Angina pectoris caused by coronary heart disease; Cost-benefit analysis; Contingent valuation method; Net benefit; Incremental net benefit
阅读数: 348 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!